Major stock indexes closed higher on Friday, driven by corporate earnings reports from tech firms like Alphabet and Amazon.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.

Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell ...

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. Ken Fisher is the founder and executive chairman of Fisher Asset Management ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...